Menu Close

New York State Common Retirement Fund Sells 2,110 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

view original post

New York State Common Retirement Fund trimmed its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 7.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,425 shares of the medical research company’s stock after selling 2,110 shares during the quarter. New York State Common Retirement Fund owned 0.08% of Bio-Rad Laboratories worth $14,320,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Bio-Rad Laboratories by 0.7% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 67,331 shares of the medical research company’s stock valued at $37,923,000 after acquiring an additional 452 shares in the last quarter. AlphaCrest Capital Management LLC raised its holdings in shares of Bio-Rad Laboratories by 836.1% in the fourth quarter. AlphaCrest Capital Management LLC now owns 2,696 shares of the medical research company’s stock valued at $2,037,000 after acquiring an additional 2,408 shares in the last quarter. Globeflex Capital L P bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at about $178,000. Stephens Inc. AR raised its holdings in shares of Bio-Rad Laboratories by 16.5% in the first quarter. Stephens Inc. AR now owns 566 shares of the medical research company’s stock valued at $319,000 after acquiring an additional 80 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Bio-Rad Laboratories by 1.9% in the fourth quarter. JPMorgan Chase & Co. now owns 30,739 shares of the medical research company’s stock valued at $23,225,000 after acquiring an additional 573 shares in the last quarter. 63.66% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BIO has been the topic of several analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $700.00 target price on shares of Bio-Rad Laboratories in a research note on Friday, April 29th. TheStreet lowered Bio-Rad Laboratories from a “b-” rating to a “c+” rating in a research note on Thursday, April 28th. Finally, Citigroup cut their target price on Bio-Rad Laboratories from $750.00 to $700.00 and set a “buy” rating on the stock in a research note on Friday, July 8th.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $539.65 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $462.61 and a fifty-two week high of $832.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.22 and a current ratio of 5.30. The stock’s 50-day simple moving average is $513.32 and its 200-day simple moving average is $545.67.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The medical research company reported $3.38 earnings per share for the quarter, topping analysts’ consensus estimates of $2.46 by $0.92. Bio-Rad Laboratories had a positive return on equity of 3.82% and a negative net margin of 67.66%. The business had revenue of $691.10 million for the quarter, compared to analyst estimates of $664.60 million. During the same quarter in the previous year, the firm earned $3.54 earnings per share. The company’s revenue was down 3.5% on a year-over-year basis. As a group, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 14.28 EPS for the current year.

Bio-Rad Laboratories Company Profile

(Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Recommended Stories

Receive News & Ratings for Bio-Rad Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bio-Rad Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.